

Supplementary table 7: Adverse events

	qHPV (n=64)	Placebo (n=62)	p-value
None	6 (9.4%)	7 (11.3%)	0.78
Any	58 (90.6%)	55 (88.7%)	0.72
- Vaccine-related‡	43 (67.2%)	38 (61.3%)	0.49
At injection site*	24 (37.5%)	10 (16.1%)	0.007
Systemic	57 (89.1%)	54 (87.1%)	0.73
- Vaccine-related‡	36 (56.3%)	34 (54.8%)	0.87
Serious	3 (4.7%)	4 (6.5%)	0.72
- Vaccine-related‡	0 (0%)	0 (0%)	-
- Death	0 (0%)	0 (0%)	-

Numbers are n, (%) for participants having experienced at least one AE within the category. Abbreviations:

qHPV, quadrivalent human papillomavirus vaccine

* pain, erythema, swelling during the seven days following vaccination; all injection site adverse experiences were considered vaccine-related.

‡ Determined by the investigator to be possibly, probably, or definitely related to the vaccine.